Serum biomarkers for chagas disease

Abstract

The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying Chagas disease status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as infected with Chagas disease or non-infected. The biomarkers can be detected by SELDI mass spectrometry.

1 . A method for qualifying Chagas disease status in a subject comprising:
 a. measuring at least one biomarker in a biological sample from the subject, wherein the at least one biomarker is selected from the group consisting of the biomarkers of Table 1 and Tables 2A-2X; and   b. correlating the measurement with Chagas disease status.   
     
     
         2 . The method of  claim 1 , wherein the at least one biomarker is selected from the group consisting of the biomarkers of Table 3 and 4. 
     
     
         3 . The method of  claim 1 , wherein the at least one biomarker is selected from the group consisting of: MIP-1a, Apo 1A, Fibronectin, C3 anaphylatoxin, and M110. 
     
     
         4 . The method of  claim 1 , further comprising measuring each of: MIP-1a, Apo 1A, Fibronectin, C3 anaphylatoxin, and M110. 
     
     
         5 . The method of  claim 4 , further comprising measuring an additional biomarker listed in Table 1 and Tables 2A-2X. 
     
     
         6 . The method of  claim 1 , further comprising measuring one or more biomarkers selected from the group of biomarkers of molecular masses 4.4, 4.8, 7.8, 8.9, 9.3, 13.6, 16.3, 28.7, and 54.04 kDa. 
     
     
         7 . The method of  claim 1 , wherein the at least one biomarker is measured by (i) capturing the biomarker on an adsorbent surface of a SELDI probe and detecting the captured biomarkers by laser desorption-ionization mass spectrometry or by (ii) immunoassay. 
     
     
         8 . (canceled) 
     
     
         9 . The method of  claim 1 , wherein the sample is serum. 
     
     
         10 . The method of  claim 1 , wherein the correlating is performed by a software classification algorithm. 
     
     
         11 . The method of  claim 1 , wherein the Chagas disease status is selected from chronic symptomatic, chronic asymptomatic, acute uninfected. 
     
     
         12 . The method of  claim 1 , wherein the Chagas disease status is selected from Chagas versus healthy. 
     
     
         13 . The method of  claim 1 , wherein the at least one biomarker is selected from the biomarkers of Table 3. 
     
     
         14 . The method of  claim 1 , wherein the Chagas disease status is selected from Chagas versus non-Chagas. 
     
     
         15 . The method of  claim 1 , wherein the at least one biomarker is selected from the biomarkers of Table 4. 
     
     
         16 . The method of  claim 1 , wherein the at least one biomarker is selected from the biomarkers of molecular weight 8.351 kDa, 9.3 kDa, 7.3 kDa, 6.04 kDa, 4.4 kDa, 4.07 kDa and 5.1 kDa, as depicted in  FIGS. 7-9 . 
     
     
         17 . The method of  claim 1 , further comprising:
 c. managing subject treatment based on the status.   
     
     
         18 . The method of  claim 7 , wherein the adsorbent is a cation exchange adsorbent or a metal chelate adsorbent. 
     
     
         19 . (canceled) 
     
     
         20 . The method of  claim 17 , further comprising wherein if the measurement correlates Chagas disease:
 d. administering one or more drugs selected from the group consisting of nifurtimox, benznidazole and allopurinol.   
     
     
         21 . The method of  claim 20 , further comprising:
 e. measuring the at least one biomarker after subject management.   
     
     
         22 .- 75 . (canceled)